3Q20 interest rates lowest since 2014
Average interest rates observed in 3Q20 was the lowest since 2014 (Figure 1). With 3M-SIBOR and 3M-SOR at 44 bps and 94 bps lower than 1H20 average respectively (Figure 2), we expect banks to report NIM levels at similar or slightly lower than in 2Q20 as continued downward pressure on interest rates offsets benefits from repricing of deposit rates.
Sluggish loans growth in August reflects poor economic outlook
Loans contracted 1.03% YoY in August, as outstanding loans shrank for the sixth consecutive month (Figure 3). The poor loans performance was attributed to business loans, which fell YoY (-0.04%) for the first time since November 2016 in August (Figure 4). Consumer loans fell 2.61% YoY, but improved by 0.33% MoM, as all loans segment apart from housing loans (car loans, credit card loans, share financing and others) improve in August from a month ago.
Additional moratorium support by MAS for individuals and SMEs reduces default risks for banks
On 5 October, MAS announced that it will be providing additional support for individuals and SMEs needing assistance in loan repayments, including extension in application to various moratorium relief schemes, as well as new measures to reduce cashflow challenges faced by as a result of the economic fallout from COVID-19 (Figure 4).
Instead of a blanket deferment in loan repayment during the current loan moratorium period, the additional measures aim to allow individuals and SMEs to resume repayments at a lower quantum before easing back into repayments at levels before the moratorium period. This will partially ease cashflow challenges faced by borrowers while allowing the banks and other FIs to resume loan collections that can prevent cliff effect from a sudden deterioration in loan quality resulting from borrowers who are unable to resume full payments at the onset of the loan moratorium expiry.
Borrowers will also be allowed a longer window to apply for loan moratorium as long as they are not more than 90 days past due when applying for the relief measures.
As of 2Q20, the three banks have an aggregate of close to S$100bn of loans under moratorium (Figure 5). The higher portion of loans under moratorium for OCBC and UOB is due to higher exposure in Malaysia, whereby loan moratoriums are automatically granted for loans in Malaysian. We expect loans under moratorium to taper in 4Q20 as Malaysia has exited loan moratorium period in September.
The additional support measures by MAS will allow the banks to reduce default risks from non-payments as banks will be able to begin to loan payments in FY21, albeit at a slower rate.
Securities turnover shows sustained growth while derivatives volume remain volatile
Preliminary SDAV data indicates a YoY increase of 16% from S$940mn a year ago to S$1,088mn in August (Figure 6). Derivatives volumes also seemed to have picked up in September compared to a year ago. Volumes for the top five equity index futures which makes up more than 95% of monthly equity index futures contract turnover grew by an average of 9% YoY in September (Figure 7).
The newly launched FTSE Taiwan index continues to perform well in September (Figure 8), recording more than 300,000 increase in contracts from August to offset the fall in turnover for its MSCI counterpart (-200,000 contracts MoM).
Alongside contribution from Scientific Beta and BidFX acquisitions, we expect SGX to report 10% increase in earnings YoY for 1Q21.
Investment Action
Maintain the Singapore Banking Sector at Neutral. The Singapore banking sector will continue experiencing headwinds from low interest rates as well as heightened provisions amidst the economic fallout in the short-term. Nevertheless, downside risks are mitigated due to the strong support measures provided by the government. We expect earnings to slowly recover
Re-rating Catalyst
A potential re-rating catalyst will be a better-than-expected credit profile of borrowers post-moratorium in Singapore, which can spell an earlier end to the heightened credit costs which the banks have guided for to the end of FY21.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
